STATEMENTS OF STOCKHOLDERS' DEFICIT - USD ($)	Common Stock	Additional Paid-in Capital	Retained Deficit	Total
Balance at Feb. 28, 2014	$ 131,449	$ 112,089,593	$ (112,371,664)	$ (150,622)
Balance (in shares) at Feb. 28, 2014	131,448,444
Increase (Decrease) in Stockholders' Equity
Cash contributed by S.R. Burzynski M.D., Ph.D. and related parties		355,729		355,729
FDA clinical trial expenses paid directly by S.R. Burzynski M.D., Ph.D.		2,548,598		2,548,598
Net loss			(2,892,048)	(2,892,048)
Balance at Feb. 28, 2015	$ 131,449	114,993,920	(115,263,712)	(138,343)
Balance (in shares) at Feb. 28, 2015	131,448,444
Increase (Decrease) in Stockholders' Equity
Cash contributed by S.R. Burzynski M.D., Ph.D. and related parties		252,039		252,039
FDA clinical trial expenses paid directly by S.R. Burzynski M.D., Ph.D.		1,790,386		1,790,386
Net loss			(2,005,100)	(2,005,100)
Balance at Feb. 29, 2016	$ 131,449	$ 117,036,345	$ (117,268,812)	$ (101,018)
Balance (in shares) at Feb. 29, 2016	131,448,444